Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study of SHR-1701 Combined With Apatinib as Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Targeted and Immune Therapies

NCT07749859 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT07749859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07749859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study of SHR-1701 Combined With Apatinib as Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Targeted and Immune Therapies
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
December 31, 2028
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced unresectable hepatocellular carcinoma